Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jun 20, 2022
SOUTH PLAINFIELD, N.J. , June 20, 2022 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21 st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy.
Additional Formats
Jun 09, 2022
SOUTH PLAINFIELD, N.J. , June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing.
Additional Formats
Jun 06, 2022
SOUTH PLAINFIELD, N.J. , June 6, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42 nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m. ET      The presentation will be webcast live on the
Additional Formats
Jun 03, 2022
- Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOUTH PLAINFIELD, N.J. , June 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B
Additional Formats
May 31, 2022
- Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date - SOUTH PLAINFIELD, N.J. , May 31, 2022 /PRNewswire/ -- PTC Therapeutics, Inc.
Additional Formats
May 20, 2022
– First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive function – – Conference call scheduled for Monday, May 23 , at 8 a.m. ET – SOUTH PLAINFIELD, N.J.
Additional Formats
May 03, 2022
- $149 million total revenue representing impressive 26% year-over-year growth – - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease – - CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch – SOUTH PLAINFIELD, N.J.
Additional Formats
Apr 29, 2022
SOUTH PLAINFIELD, N.J. , April 29, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Bank of America Securities 2002 Healthcare Conference Tuesday, May 10 at 5:20 p.m.
Additional Formats
Apr 19, 2022
SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3 , at
Additional Formats
Apr 14, 2022
- CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with
Additional Formats